Skip to main content

Table 4 On-treatment COPD-related medical costs for the UMEC/VI and TIO cohorts

From: Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study

 

UMEC/VI (N = 3929)

TIO (N = 3929)

Cost difference (95% CI)

p value

On-treatment period, mean days (SD) [median]

203.0 (249.0) [90]

139.4 (197.9) [60]

–

–

COPD-related medical costs, $US 2019 PPPM, mean (SD)

 Total medical costs

867 (3259)

1095 (7958)

− 228 (− 504, − 15)

0.028

 Hospitalizations

406 (1837)

461 (2414)

− 54 (− 161, 49)

0.309

 ER visits

123 (2275)

125 (707)

− 2 (− 38, 36)

0.914

 Outpatient visits

296 (1129)

462 (7433)

− 166 (− 409, − 7)

0.036

 Other visits

41 (181)

48 (176)

− 6 (− 15, 3)

0.184

  1. CI, confidence interval; COPD, chronic obstructive pulmonary disease; PPPM, per patient per month; SD, standard deviation; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol